Skip to main content
Seeing the difference Ac-225 could make to cancer patients made Raina Setzer want to come to ORNL to directly work with the isotope. Credit: Allison Peacock/ORNL, U.S. Dept. of Energy

Raina Setzer knows the work she does matters. That’s because she’s already seen it from the other side. Setzer, a radiochemical processing technician in Oak Ridge National Laboratory’s Isotope Processing and Manufacturing Division, joined the lab in June 2023.

Sam Hollifield displays a prototype of the Secure Hijack, Intrusion and Exploit Layered Detector, or SHIELD, the device monitoring the cybersecurity of the semi-truck. Credit: Lena Shoemaker/ORNL, U.S. Dept. of Energy

As vehicles gain technological capabilities, car manufacturers are using an increasing number of computers and sensors to improve situational awareness and enhance the driving experience.

State and Local Economic Development Award

A partnership of ORNL, the Tennessee Department of Economic and Community Development, the Community Reuse Organization of East Tennessee and TVA that aims to attract nuclear energy-related firms to Oak Ridge has been recognized with a state and local economic development award from the Federal Laboratory Consortium.

A group of people standing outside in front of trees and buildings

Nine student physicists and engineers from the #1-ranked Nuclear Engineering and Radiological Sciences Program at the University of Michigan, or UM, attended a scintillation detector workshop at Oak Ridge National Laboratory Oct. 10-13.

MDF Exterior

ORNL scientists will present new technologies available for licensing during the annual Technology Innovation Showcase. The event is 9 a.m. to 3 p.m. Thursday, June 16, at the Manufacturing Demonstration Facility at ORNL’s Hardin Valley campus.

Targeted alpha therapy can deliver radiation to specific cells, with minimal effect on surrounding, healthy cells. Credit: Michelle Lehman and Jaimee Janiga/ORNL, U.S. Dept. of Energy

A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.

Sandra Davern performs cell based assays to evaluate cell death and DNA damage in response to radiation in order to gain a better understanding of how radioisotope nanoparticles affect the human body.

When Sandra Davern looks to the future, she sees individualized isotopes sent into the body with a specific target: cancer cells.